Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 10, 2017 07:45 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Therapy for β-Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting

ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 10, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today announced the presentation of new data on CTX001, an investigational CRISPR...
December 07, 2017 07:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in β-thalassemia

ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today announced the submission of a Clinical Trial Application (CTA) for CTX001 in...
December 05, 2017 08:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Medicine for β-Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting

ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today announced that Dr. Bill Lundberg, Chief Scientific Officer of CRISPR, is scheduled to...
November 28, 2017 08:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for serious diseases,...
November 13, 2017 08:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Announces Appointment of Michael Tomsicek as Chief Financial Officer

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
November 13, 2017 05:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs

ZUG, Switzerland and CAMBRIDGE, Mass. and TÜBINGEN, Germany, and BOSTON, Nov. 13, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating...
November 10, 2017 20:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR-T Therapies at SITC Annual Meeting

- CRISPR-based CAR-T cell therapy candidates targeting CD19+, BCMA and CD70 demonstrate high editing rates, and potent anti-tumor activity in preclinical models -- Expanding applicability of...
November 08, 2017 16:05 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Announces Third Quarter 2017 Financial Results and Provides Business Update

- On track to begin first company-sponsored clinical trial of a CRISPR-based therapeutic -- Wholly-owned CRISPR-based CAR-T programs advancing rapidly -- New collaborations enhance work in...
November 07, 2017 08:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics to Present New Data on Allogeneic CRISPR-based CAR-T Program and Host Investor Reception at the 32nd Annual Society for Immunotherapy of Cancer Meeting

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for serious diseases,...
October 13, 2017 08:30 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance to Collaborate with University of Alabama at Birmingham on Gene-edited Treatments for Friedrich’s Ataxia

ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 13, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for serious diseases,...